Items tagged with Drug-resistant TB
Webinar: Treatment of pediatric MDR-TB - lessons from the field (post)
RESIST-TB will host a webinar on 4 May 2022 on the latest childhood treatments and guidelines of the World Health Organization in the pediatric multidrug-resistant TB (MDR-TB) regimens and lessons from the field.
Outcomes, safety of weight-based bedaquiline in children with multidrug-resistant TB (post)
Weight-based dosing of bedaquiline for multidrug/rifampicin-resistant (MDR/RR) tuberculosis (TB) infection was safe and effective among children with and without HIV coinfection, according to findings published in Clinical Infectious Diseases.
CinA protein contributes to drug tolerance in Mycobacterium tuberculosis (post)
Weill Cornell Medicine researchers have identified a protein in Mycobacterium tuberculosis (Mtb) that contributes to drug tolerance, a phenomenon that allows bacteria to survive treatment with drugs that would normally kill them.
Researchers identify rare genetic markers of drug-resistant TB (post)
Search for rare mutations in bacterial genome could lead to better diagnostics and treatments – reducing morbidity caused by the deadly disease.
20% of multidrug-resistant TB cases in children could be averted by household testing and treatment (post)
New modelling study suggests that testing household contacts and preventive treatment could avert almost 4,000 deaths in children under 15 globally every year.
Linezolid dosing as part of three-drug regimen for drug-resistant TB (post)
In February, the CDC released provisional guidance for the use of pretomanid as part of the bedaquiline, pretomanid and linezolid (BPaL) regimen to treat drug-resistant tuberculosis.
Can drug-resistant TB be reversed with a novel small molecule? Scientists turn to an animal model to find out (post)
Tuberculosis is a major public health concern, an ancient bacterial disease that has claimed the lives of kings, presidents, poets and at least one star of Hollywood's silver screen-era. Yet even now in the 21st century, it's still impossible to shake the scourge. TB kills someone around the globe every 22 seconds, the World Health Organization estimates.
Hundreds of new drug targets to combat TB (post)
Tuberculosis is a stubborn disease, born of yet more stubborn microbes. While many bacterial infections resolve within days of starting antibiotics, tuberculosis often refuses to budge for around six months and, in some cases, may never release its vice grip on the human body. It claimed 1.5 million lives in 2020, second only to COVID-19 among infectious diseases.
New antibiotics could tackle drug-resistant TB (post)
Infection by Mycobacterium tuberculosis kills 1.5 million people worldwide every year. Antibiotics to treat TB exist, but in recent years, multi-drug resistant (MDR), extensively drug-resistant (XDR) and totally drug-resistant (TDR) strains of the bacterium have developed. According to a new study publishing May 31st in the open-access journal PLOS Biology by Ho-Yeon Song of Soonchunhyang University in the Republic of Korea and colleagues, a new class of antibiotics is highly effective against drug-resistant tuberculosis. If validated in clinical trials, the new drug class would represent a major advance in the treatment of tuberculosis.
RESIST-TB May 2022 newsletter (post)
RESIST-TB released its May 2022 newsletter with the latest research publications on drug-resistant TB.
Page 75 of 117 · Total posts: 0
←First 74 75 76 Last→